Solventum (SOLV) is a US-listed Healthcare company in Medical - Care Facilities with a market capitalization of
3.5B, trading at $77.94 on the NYSE. This SniperIQ fundamentals page covers Solventum's valuation (P/E 9.5x, P/B 2.7x), profitability (net margin 17.3%), revenue ($8.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market Cap
3.5B
P/E (TTM)9.5x
Net Margin17.3%
Revenue (FY25)$8.3B
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is Solventum's market cap?
Solventum (SOLV) has a market capitalization of approximately
3.5B, trading at $77.94 on the NYSE. Market cap moves with the live share price.
What is Solventum's P/E ratio?
Solventum's trailing twelve-month P/E ratio is 9.5x, with a price-to-book (P/B) of 2.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Solventum?
Solventum runs a net profit margin of 17.3%, a gross margin of 53.7%, and an operating margin of 25.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Solventum generate?
Solventum reported revenue of $8.3B for fiscal year 2025, with net income of
.6B and earnings per share (EPS) of 8.94. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Solventum pay a dividend?
Solventum does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Solventum financially healthy?
Solventum carries a debt-to-equity ratio of 1.02x and a current ratio of 1.07x, with a market beta of 0.72. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Solventum a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Solventum (SOLV) the key facts are: market cap
3.5B, P/E 9.5x, revenue $8.3B, 52-week range 62.38-88.2. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Solventum's full fundamentals live
Get Solventum's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.